MedTrace Logo

Evaluation of a Novel Ocular Lubricating Eye Drop

NCT07593404 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-19

No results posted yet for this study

Summary

The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye.

In Part 1, participant will receive 1 drop of ABR2 in one eye and through assessments over a 1-hour period.

In Part 2, participant will use 1 drop of ABR2 at least two times a day for 28-day period (may use up to 4 times a day as needed) This is a single arm, open label study with no placebo or comparative arm.

Conditions

  • Dry Eye Syndrome (DES)

Interventions

DRUG

Part 2 ABR2 At least twice a day for 28 days

Use ABR2 at least BID, up to QID for 28 days

DRUG

Part 1: ABR2 single dose in one eye

Receive a single dose in one eye only

Sponsors & Collaborators

  • University of Waterloo School of Optometry and Vision Science

    collaborator UNKNOWN

  • Pleryon Therapeutics (Hangzhou) Limited

    lead INDUSTRY

Principal Investigators

  • Charis Lau, PharmD, OD · Pleryon Therapeutics

  • Jill Woods, MSc, MCOptom · Centre for Ocular Research & Education, University of Waterloo

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-01-31
Completion
2027-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07593404 on ClinicalTrials.gov